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Abstract
Background: Malnutrition and malaria frequently coexist in sub-Saharan African countries. Studies on efficacy of
antimalarial treatments usually follow the WHO standardized protocol in which severely malnourished children are
systematically excluded.
Few studies have assessed the efficacy of chloroquine, sulfadoxine-pyrimethamine and quinine in severe acute
malnourished children. Overall, efficacy of these treatments appeared to be reduced, attributed to lower immunity and
for some antimalarials altered pharmacokinetic profiles and lower drug concentrations. However, similar research on the
efficacy and pharmacokinetic profiles of artemisinin-combination therapies (ACTs) and especially artemether-lumefantrine
in malnourished children is currently lacking.
The main objective of this study is to assess whether artemether-lumefantrine is less efficacious in children suffering from
severe acute malnutrition (SAM) compared to non-SAM children, and if so, to what extent this can be attributed
to a sub-optimal pharmacokinetic profile.
Methods/design: In two sites, Ouelessebougou, Mali and Maradi, Niger, children with uncomplicated
microscopically-confirmed P. falciparum malaria aged between 6 and 59 months will be enrolled. Two non-SAM children
will be enrolled after the enrolment of each SAM case. Children with severe manifestations of malaria or complications of
acute malnutrition needing intensive treatment will be excluded.
Treatment intakes will be supervised and children will be followed-up for 42 days, according to WHO guidance
for surveillance of antimalarial drug efficacy. Polymerase Chain Reaction genotyping will be used to distinguish
recrudescence from re-infection. SAM children will also benefit from the national nutritional rehabilitation program.
Outcomes will be compared between the SAM and non-SAM populations. The primary outcome will be adequate clinical
and parasitological response at day 28 after PCR correction, estimated by Kaplan-Meier analysis. To assess the
pharmacokinetic profile of lumefantrine, a sparse sampling approach will be used with randomized allocation
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of sampling times (5 per child). A total of 180 SAM children and 360 non-SAM children will be recruited during
the 2013 and 2014 malaria seasons.
Discussion: This study will provide important information that is currently lacking on the effect of SAM on therapeutic
efficacy and pharmacokinetic profile of artemether-lumefantrine. If it shows lower therapeutic efficacy and decreased
lumefantrine concentrations, it would inform dose optimization studies in SAM children.
Trial registration: ClinicalTrials.gov: NCT01958905
Keywords: Malaria, Severe acute malnutrition, Artemether-lumefantrine fixed combination, Pharmacokinetics, Efficacy,
Niger, Mali
Background
Malnutrition and Plasmodium falciparum malaria are
two major public health problems in sub-Saharan Africa.
In Sahel countries, both diseases have a marked season-
ality, with concomitant peaks in the second half of the
year. The rainy season, roughly from July to October,
corresponds with the high transmission season of mal-
aria, and to the hunger gap period. In these countries,
children under 5 years of age are the highest-risk popu-
lation for both diseases, and it has been estimated that
more than 50 % of child deaths were attributable to mal-
nutrition potentiating effects on infections [1, 2].
Child malnutrition is a diverse spectrum: stunting
i.e. chronic malnutrition reflected by a low height-for-age,
and wasting i.e. acute malnutrition reflected by a low
weight-for-height. The latter allows detecting acute or
sub-acute episodes, and is a good predictive marker of
short-term mortality. It is an indication to refer children
into nutritional rehabilitation programs [3], together
with the measurement of mid-upper arm circumference
(MUAC). Anthropometric standards have been updated
by the WHO in 2006 [4]. Moderate acute malnutrition
(MAM) is defined by a weight-for-height z-score be-
tween -3 and -2, or MUAC between 115 and 125 mm,
whereas severe acute malnutrition (SAM) is defined by
z-score < -3or MUAC <115 mm.
Child malnutrition is associated with a higher risk of in-
fections and infectious episodes contribute to deteriorate
the nutritional status [5], resulting in a vicious circle
malnutrition-infection-malnutrition. In the specific con-
text of malaria infections, the interactions with malnutri-
tion are complex. The question of the impact of child
malnutrition on malaria susceptibility is still debated, with
conflicting results in the literature: few studies have found
an increased risk of malaria and higher parasitemia in
children with stunting, linked to decreased specific anti-
malarial immunity [6, 7]. Other studies have shown a
higher risk of malaria-related severe anemia in wasted
children [8, 9] and stunted children [10]. Overall, children
with low weight/age are at higher risk to develop malaria
in general, and severe episodes in particular [9, 11], with
lower parasitemia than in non-malnourished children [12].
It is also clearly established that malnutrition (whether
acute or chronic) is an important risk factor for malaria-
related mortality [5, 10, 13, 14]. Conversely, malaria could
favor the occurrence of SAM, and it has been shown that
implementing malaria preventive strategies like insecticide-
treated bednets improved the nutritional status of targeted
populations [8].
Relevance
Generally, studies on efficacy of antimalarial treatments
follow the WHO standard protocol [15] in which children
with SAM are systematically excluded. Consequently, the
efficacy of antimalarial drugs in the SAM population has
been poorly documented by intervention studies. Observa-
tional studies have been published regarding the efficacy of
chloroquine [16], sulfadoxine-pyrimethamine (SP) [17] and
cotrimoxazole [17]. Overall, efficacy of these treatments ap-
peared to be reduced in children with SAM. Additionally,
one study showed that resistance to chloroquine and SP
was more frequent among malnourished children [18].
Finally, one study showed that the protective efficacy of
intermittent preventive treatment with SP was impaired in
malnourished children and incriminated altered pharmaco-
kinetic (PK) profile and immune response [10].
Research on the efficacy of artemisinin-combination ther-
apies (ACTs) in malnourished children is greatly lacking.
One case of treatment failure has been reported in a child
with SAM treated with artemether-lumefantrine (AL) in
India, without evidence of genotype resistance [19]. The au-
thors hypothesized that the failure could be due to altered
distribution and increased clearance of the drug, though
PK measurements were not performed. The first longitu-
dinal efficacy study in malnourished children compared AL
and dihydroartemisinin-piperaquine and reported good
efficacy (less than 1 % failure rate) [20]. A second recently
published study compared the efficacy of artesunate-
amodiaquine (ASAQ) combination in DRC between SAM
and non-SAM children [21], and did not show evidence for
decreased efficacy in children with SAM. However, the
SAM children had lower baseline parasitemia. Of interest,
none of these two studies measured drug concentrations.
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In the population of malnourished children, specific PK
properties might alter the efficacy of antimalarials. Malnu-
trition is associated with increased total body water leading
to increased volume of distribution of drugs [22]. Moreover,
intestinal malabsorption and villous atrophy are frequent
[23]. Both mechanisms contribute to lower drug concentra-
tions. Few PK studies of antimalarials were conducted in
malnourished children. They all concerned chloroquine
and quinine, and indeed showed that the concentration
achieved might be sub-optimal [24–27]. The PK profile of
ACTs has never been assessed in children with SAM. In
particular, no study has been performed regarding the PK
of AL, which is currently the first-line regimen most com-
monly used globally including in high burden Sub Saharan
countries.
Further studies evaluating the effect of malnutrition on
ACTs efficacy are warranted. These studies should also as-
sess PK of ACTs in severely malnourished children. Unless
drug concentrations are measured, it is impossible to distin-
guish clinical treatment failure resulting from an inadequate
drug exposure from failure due to drug-resistant parasites.
The MAL-NUT study aims to address the lack in know-
ledge regarding the efficacy and PK of AL in children with
SAM. AL is becoming even more widely used as first
line treatment recommended in Sahel countries, with the
implementation of malaria seasonal chemoprophylaxis
with SP plus Amodiaquine precluding the use of artesunate-
amodiaquine and artesunate-SP in these areas.
Hypothesis and aims
The research question is: Is the current recommended
dose of AL for the treatment of uncomplicated malaria
less efficacious in the children with severe acute malnu-
trition (SAM children) compared to the non-SAM children
and is PK in cause? We hypothesize that AL efficacy might
be impaired in SAM children, due to altered lumefantrine
PK profile in this population.
The study aims to assess whether the current treat-
ment dose is adequate for SAM children. It is expected
that results will inform further recommendations for
malaria treatment in this important target population.
The primary objective of the study is to compare the
rates of adequate clinical and parasitological response
(ACPR), after PCR correction, between SAM and non-
SAM children, during 28 days of follow-up.
The secondary objectives are:
– To compare the day 7 lumefantrine concentration
and PK profile of lumefantrine between SAM and
non-SAM children (The PK of artemether will not
be assessed due to feasibility concerns)
– To assess the effect of malnutrition on i) therapeutic
efficacy, ii) PK profile of lumefantrine, with
adjustment for other cofactors
– To compare the time to parasite clearance between
SAM and non-SAM children
– To compare the rates of different types of failure
(early treatment failure (ETF), late clinical failure
(LCF), late parasitological failure (LPF)) between
SAM and non-SAM children;
– To evaluate the relationship between treatment
failure and the concentration of lumefantrine in the
blood;
– To compare the rates of reinfection and
recrudescence during a follow-up period of 42 days
between SAM and non-SAM children; and
– To compare the nature and frequency of adverse
events between SAM and non-SAM children.
As an exploratory objective, we also propose to evalu-
ate the effect of malnutrition on the acquisition of spe-
cific antimalarial immunity. Malnutrition is known to
cause relative immunosuppression, but very few studies
documented its effect on specific antimalarial antibodies.
We will compare the level of anti-AMA-1 antibodies at
baseline between SAM and non-SAM children, after
adjustment for age.
Methods/design
Study design and sample size
MAL-NUT is a non-randomized non-blinded compara-
tive trial designed to compare the efficacy of AL and
the lumefantrine pharmacokinetic profile in SAM versus
non-SAM children. The two groups to be compared
will not be randomly allocated since they include
different populations of children. Similarly, blinding is
not applicable.
Enrolled children will receive AL orally at the WHO-
recommended weight-based dose over 3 days under dir-
ectly observed treatment, and will be followed prospectively
for 42 days according to the standardized WHO methods
for surveillance of antimalarial drug efficacy in high trans-
mission settings [15].
Follow-up will allow detecting early and late clinical or
parasitological failure, with PCR genotyping to distinguish
recrudescence from reinfection. The lumefantrine PK pro-
file will be assessed using a population-based approach
to restrict the number of samples required per child.
Sample size calculations were designed to detect a
minimum crude difference in the proportion of adequate
clinical and parasitological response (ACPR) between
SAM and non-SAM children, with a ratio of 1/2 be-
tween the two groups (to ease the recruitment of SAM
children). A total number of 540 children (180 SAM and
360 non-SAM) would allow to detect a minimum differ-
ence of 8 % in ACPR proportion (87 % in SAM versus
95 % in non-SAM children), with a statistical power of
at least 80 % and a 2-sided significance level of 5 %, and
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15 % expected missing endpoints. Two thirds of the
children will be enrolled in Mali during the 2013 and
2014 malaria seasons, and one third will be enrolled in
Niger during the 2014 malaria season.
Settings
The MAL-NUT study will be conducted in two sites,
Oulessebougou in the region of Koulikoro and Maradi
in the district of Maradi, located in in the south of Mali
and Niger respectively. In both countries, malaria trans-
mission is seasonal with an annual peak of high trans-
mission during and shortly after the rainy season,
usually between July and December. AL is one of the
recommended first-line malaria treatments. Since 2012,
seasonal malaria chemoprevention (SMC) with SP and
amodiaquine has been adopted by both countries and is
being implemented in several areas (including 4 of the
14 sub districts of the Ouelessebougou district in Mali,
and the Madarounfa district neighboring the Maradi
district in Niger), but not in the areas were enrolments
will be conducted.
Regarding malnutrition, despite progress its prevalence
remains at the emergency level in Mali, and Niger remains
the country the most affected worldwide [28]. In the
Koulikoro region of Mali, the prevalence of global
acute malnutrition (moderate or severe) in children
under five was estimated to 8.6 % [6.7–9.5], and that
of SAM to 1.8 % [1.0–2.2] in 2012 according to the
country’s Demographic and Health Survey (DHS). In
the region of Maradi, Niger, those figures were re-
spectively 16.2 % [14.2–18.5] and 2.5 % [1.8–3.6]
(Niger DHS 2012).
In Mali, the study will be conducted in the district hos-
pital of Ouelessebougou, located in the Koulikoro region,
about an hour’s drive from Bamako. This hospital hosts the
Malaria Research and Training Centre (MRTC) for clinical
research activities, and a nutritional rehabilitation program
conducted by the Medical Alliance Against Malaria.
In Niger, children will be recruited in the primary care
health center of Andoumè in Maradi city, where malnu-
trition activities are supported by UNICEF. In Maradi,
Epicentre has a permanent research center that has been
collaborating with the Ministry of Health on malnutri-
tion and malaria research for many years including clin-
ical trials.
Participants
The study population will consist of children aged 6–59
months with uncomplicated Plasmodium falciparum
malaria (confirmed by thick and thin blood films), and
whose parents or guardians have given their free and
informed written consent to participate in the study.
Eligibility criteria
A child will be eligible to be enrolled in the study if
he/she meets all the inclusion criteria listed below:
 Age between 6 and 59 months
 Weight ≥ 5 kg
 Axillary temperature ≥ 37.5 °C or history of fever
during the previous 24 h as reported by the parent/
guardian
 P. falciparum monoinfection confirmed on blood
film
 Parasitic density between 1,000 and 200,000 asexual
forms/μL of blood.
 High probability of compliance with follow-up visits
(no near-term travel plans)
 Written consent of a parent or guardian who is at
least 18 years of age
 According to the group: in SAM children, weight-for-
height z-score < -3 SD or MUAC <115 mm and/or
bilateral edema, and in non-SAM children, weight-
for-height z-score ≥ - 3 SD, and MUAC ≥ 115 mm and
absence of edema.
A child will not be eligible if at least one of the exclu-
sion criteria listed below is present:
 General danger signs or signs of severe malaria as
defined by the WHO;
 Mixed or mono-infection with another Plasmodium
species detected by microscopy;
 Severe anemia (hemoglobin <5 g / dL);
 Known underlying chronic or severe disease
(e.g. HIV/AIDS, TB, cardiac, renal or hepatic
disease, sickle cell);
 Presence of febrile conditions due to diseases other
than malaria which could alter the outcome of the
study;
 Known history of hypersensitivity or contra-indication
to any of the study medications: artemether,
lumefantrine (first-line medications), or artesunate,
amodiaquine (rescue medications)History of a full
treatment course with AL in the past 14 days
 Height-for-age < -3 Z scores (severe chronic
malnutrition)
 Severe complications of malnutrition requiring
hospitalization in intensive care or stabilization
Screening and enrolment
The definition of severe acute malnutrition is a weight-
for- height < -3 Z score according to the WHO standards
(2006) and / or MUAC less than 115 mm and/or pres-
ence of bilateral edema [4]. Children meeting this defin-
ition will be recruited in the SAM group; non-severely
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malnourished children without exclusion criteria will be
enrolled in the non-SAM group.
Screening
To recruit SAM children, children presenting at the
nutritional center, meeting the following criteria and
interested to participate in the study will be referred to
the study staff: Aged 6 to 59 months, SAM according to
WHO definition [4], fever or history of fever, no danger
signs, positive malaria HRP2 rapid diagnostic test
(RDT). The study staff will then explain to the parent or
a guardian over 18 years about the overall study objec-
tives, procedures and obligations attached to the study
participation. If he/she agrees, a capillary blood sample
will be taken from a finger prick for thick blood film
microscopy and hemoglobin concentration assessments.
Regarding the enrolment of non-SAM children, mal-
aria cases will be sought at the routine pediatric consult-
ation. Children with fever or a history of fever and
positive RDT who are interested to participate into the
study will be referred to the study staff and after in-
formed consent is obtained, a capillary blood sample will
be taken from a finger prick for thick blood film and
measurement of hemoglobin concentration. Enrolments
will be limited to the first two eligible non-SAM children
received after the enrolment of a SAM child (ideally
within an interval of one week), to allow carrying out in-
clusions in parallel for the two study groups, with benefit
in terms of representativeness of the study population
throughout the malaria season.
Enrolment
Screening blood films will be read on-site. If the parasite
density is between 1000 and 200 000 parasites per
microliter, the child will be referred to the clinical inves-
tigator who will complete the eligibility screen. Eligible
patients will be enrolled in the study and assigned an
identification number after written informed consent
has been obtained.
Intervention
Antimalarial treatment under evaluation
The treatment under evaluation is artemether 20 mg -
lumefantrine 120mg: Coartem® Novartis (Basel, Switzerland)
will be administered six times, twice daily for 3 days
(1 tablet per intake for bodyweights between 5 and
14.99 Kg; and 2 tablets for those weighing between
15 and 24.99 Kg).
The interval between the first and second administra-
tion is 8 +/-1 h, then subsequent intakes will be admin-
istered in the morning and evening, 12 h +/- 2 h apart,
i.e. 24, 36, 48 and 60 h after the first dose. To improve
absorption, treatment intake will be associated with fat
intake. In non-SAM children, the tablets should be
administered with a glass of milk, or in the middle of a
breastfeeding. In SAM children, treatment should be
administered with ready-to-use therapeutic food (RUTF)
or therapeutic milk.
All AL doses will be directly observed by the study
nurse. Patients will then remain under observation for
30 min. If vomiting occurs, a second dose should be
administered. If the child vomits after the second dose,
he will be removed from the study and rescue treatment
will be administered.
Additional treatments and medications
All children will receive an insecticide-treated bed net at
enrolment.
One tablet of 5 mg of folic acid will be administered to
each child at Day 0. A systematic deworming by alben-
dazole will be administered at Day 14, according to na-
tional guidelines. If the axillary temperature exceeds
38.5 °C and external cooling measures are insufficient, a
dose of 15 mg/kg of paracetamol can be administered
and repeated every 6 h. Iron supplementation will be
administered in case of anemia for children not requir-
ing nutritional supplements (otherwise, iron is already
included in nutritional supplements).
Additionally in SAM children, feeding medications
and associated therapies will be provided according to
the national nutrition programs of Mali and Niger:
RUTF (Plumpynut®) will be provided, corresponding to
an intake of approximately 170 kcal/kg/day. The child
will be closely monitored, if his nutritional status does
not improve or if he encounters a medical complication,
he will be transferred to the intensive care unit. A sys-
tematic treatment with oral amoxicillin will be adminis-
tered for 7 days, twice a day at the dosage of 50 to 100
mg/Kg/day. A dose of vitamin A will be administered at
Day 28, except for children who have already received a
dose in the previous 4 months. Finally, SAM children
without prior vaccination will be vaccinated against
measles at Day 28.
Other drugs may be administered for concomitant
diseases. However, antibiotics with antimalarial activity
will be prohibited for the duration of follow-up, unless
no alternative treatment is available.
Rescue treatment
Antimalarial rescue treatment will be administered in
case of treatment failure, repeated vomiting or malaria
infection with species other than P. falciparum.
In case of treatment failure without signs of severe mal-
aria, children will receive Artesunate-Amodiaquine fixed
combination (ASAQ Winthrop®, Geneva, Switzerland) or-
ally, which is the second-line treatment in Mali and Niger,
administered at fixed hours for 3 days (25 mg AS /67.5 mg
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AQ under 9 Kg, 50 mg/135 mg between 9 and 18 Kg, 100
mg/270 mg above 18 Kg).
In case of treatment failure with signs of severe malaria
or oral administration impossible (repeated vomiting),
artesunate will be administered IV at a dose of 2.4 mg / kg
at 0, 12 and 24 h, and then every 24 h until the patient
can tolerate oral treatment. An alternative is the use of
artemether IM at a dose of 3.6 mg/kg on day 1 followed
by 1.6 mg/kg the following days. After that, a full 3-day
course of ASAQ should be administered.
After rescue treatment is administered, the weekly
clinical follow-up will continue until D 42 to allow the




At baseline, socio-demographic and anthropometric char-
acteristics, medical history, clinical data, and biological
data will be collected: in addition to the blood film and
hemoglobin concentration performed at screening, capil-
lary blood will be collected from a finger prick, and a few
drops will be placed on filter paper to perform PCR geno-
typing (all children) and to measure Anti-AMA1 IgG
(sub-study restricted to children enrolled in Mali).
Antimalarial efficacy
Children will be kept under observation in the hospital
for the 72 first hours to ensure supervised administra-
tion of the treatment. On Day 1, Day 2, Day 3, a clinical
examination will be performed, axillary temperature
measured, and thick and thin blood films collected from
capillary blood. In addition, the determination of
parasite clearance time will involve extra blood films at
h6, h12, h36.
The child will return home after the study team has
noted their contact information. An insecticide-treated
mosquito net will be provided and the appointment
schedule for weekly follow-up visits will be clearly ex-
plained to the parent/caretaker.
On day 7, 14, 21, 28, 35 and 42, the child will undergo
a physical examination with temperature measurement,
and thick and thin blood films from capillary blood.
Adverse events and concomitant medications will be re-
ported. The measurement of hemoglobin concentration
will also be performed on day 28.
If the child attends the study center for an unsched-
uled visit, a physical examination will be performed. If
symptoms are suggestive of malaria, blood films will be
performed.
In case of treatment failure, capillary blood will be col-
lected on filter paper for PCR genotyping and lumefan-
trine concentration assay and the rescue treatment will
be administered.
Children not attending their appointment will be ac-
tively traced by home visitors the next morning.
For children with SAM, each weekly visit in the study will
be combined with a visit to the nutritional rehabilitation
center for monitoring and treatment of malnutrition.
The schedule of follow-up activities is summarized in
Fig. 1.
Pharmacokinetics
Lumefantrine concentrations will be analysed using a
population-based approach to restrict the number of
samples required per child [29]. To achieve adequate
precision in the estimation of PK parameters, assays will
be conducted in 150 SAM and 150 non-SAM children.
SAM children participating in the PK analysis will be the
first consecutive patients recruited in both study sites,
and non-SAM will be those recruited just after each
SAM case.
For ethical and practical reasons, wherever possible, we
will combine the PK samplings with other samplings per-
formed for assessing parasitological efficacy. PK modelers
have the following population sampling scheme: The first
collection will be performed at h6, h12, h24, h36 or h48
(time randomly allocated), the second at h60 (the evening
of day 2), the third at h72 (just before the discharge), the
fourth at day 7, and the fifth at day 14 or day 21 (randomly
allocated). An additional dosage will be made on the day of
failure, if parasitological failure occurs.
The random allocation sequence of PK sampling times
will be computer-generated by Excel before the study
starts. The randomization list with be retained in each
study site by the investigators, who will directly imple-
ment the allocation sequence (no blinding is required).
The PK of artemether and its active metabolite, dihy-
droartemisinin, will not be performed due to the heavy
burden in this vulnerable population as well as logistical
concerns as three venous blood samplings between h0 and
h8 then plasma storage and shipment at -80 °C would be
required. As an alternative, the parasite clearance will be
determined in all patients, as it is considered the best indi-
cator of impaired efficacy of the artemisinin component of
an ACT [30]. A prolonged parasite clearance in children
with SAM would support an impaired efficacy of arte-
mether, one possible cause being inadequate exposure to
artemisinins. On the other hand, an unaltered clearance
would suggest that artemisinin exposure and efficacy is
adequate. The Data Safety Monitoring Board (DSMB) will
have the responsibility to monitor closely parasite clearance
data, and to recommend a protocol amendment adding
artemether PK assessment if deemed necessary.
Laboratory methods
During this study, only capillary blood from finger pricks
will be collected. The total amount of blood required for
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each patient included will approximate 7 ml for the total
duration of follow-up.
For malaria screening, the SD Bioline® HRP2 RDT
(Gyeonggi-do, Republic of Korea) will be used.
Thick and thin blood films will be read using a 100x ob-
jective. A sample will be considered negative only after 200
microscopic fields have been evaluated. The number
of P. falciparum asexual forms on the thick film will
be counted using the technique recommended by the
WHO against at least 200 leukocytes [31]. Parasite
density will be calculated based on a hypothetical
leukocyte density of 8000 leukocytes/μL. The presence
of gametocytes will also be assessed. For internal
quality control during the study, a blinded second
evaluation of the slides will be conducted by a second
microscopist and in case of important deviation be-
tween the two readings, the procedures will be revised.
An external quality control will be carried out by an
external laboratory periodically during the study, for a
random sample of 10 % of the positive and negative
films.
Hemoglobin concentration will be determined with a
HemoCue B®-Hemoglobin brand device (Ängelholm,
Sweden) on day 0 and day 28.
PCR genotyping of malaria parasites will be performed
to differentiate between a recrudescence and a re-
infection. For this purpose, samples will be collected at
enrolment and at treatment failure (if any) on filter
paper and stored individually in re-sealable, zippered
pouches containing a desiccant and sheltered from
moisture, excessive heat and light. PCR genotyping will
be carried out at the MRTC laboratory in Bamako. PCR
adjustment consists of comparing primary infection par-
asites with those responsible for secondary infections.
Identical genotypes at the glurp, msp-2 and msp-1 loci
are a sign of treatment failure, while distinct genetic pro-
files indicate reinfection [32]. The paired pre- (day 0)
and post-treatment (day X) samples with similar geno-
types will be classified as a recrudescence (true failures),
while pairs with different genotypes will be classified as
re-infections. This analysis will also allow the complexity
of infection (single or multiple) to be determined.
For lumefantrine concentration assessment, capillary
blood will be collected in a microcapillary tube coated
with lithium heparinate, then immediately transferred to
a filter paper previously treated by the laboratory of
Cape Town (50 microliter of whole blood per spot).
Once dry, the filter papers will be stored away from heat
Fig. 1 Schedule of follow-up activities. UV, unscheduled visit ; PK, pharmacokinetics ; AL, artemether-lumefantrine ; Pf, Plasmodium falciparum. 1 if
screening parasitemia performed more than 2 h before h0. 2 first and last PK sampling times randomly allocated (first: h6 or h12 or h24 or h36 or
h48; last: day 14 or day 21). 3 In case of treatment failure, additional capillary sampling for PCR genotyping and concentration of lumefantrine. 4
Hemoglobin concentration assessed at any point during follow-up if deemed necessary according to clinical condition. 5 Restricted to patients
enrolled in Mali
Denoeud-Ndam et al. BMC Infectious Diseases  (2015) 15:228 Page 7 of 11
and excessive light and regularly sent to the Division of
Clinical Pharmacology, University of Cape Town for
analysis. Quality controls spiked by the analytical labora-
tory, specifically designed to control for the environmen-
tal conditions at the site and during storage, will be
stored and sent under the same conditions. PK assays
will be performed using liquid chromatography and tan-
dem mass spectrometry (LC MS/MS).
At h0, for children enrolled in Mali, 3 drops of capil-
lary blood will be placed on filter paper for the dosage
of anti-AMA1 specific antimalarial antibodies by Elisa
method. Analysis will be performed by MRTC, Bamako.
Outcome measures
The primary outcome of this study is the proportion of
patients having an adequate clinical and parasitological re-
sponse (ACPR) as defined by the WHO [14] on day 28,
after PCR correction. This proportion will be compared be-
tween SAM and non-SAM children. Kaplan-Meier analysis
will be used to account for censored data.
Secondary outcomes are:
– Regarding treatment efficacy
○ Corrected ACPR proportion on day 42
○ Failure proportion by type (ETF, LCF, LPF) by
day 28 and 42, as defined by WHO [14]
○ Proportion of reinfection and recrudescence
○ Time to parasite clearance and parasite
clearance half-life
– Regarding PK of lumefantrine
○ Area under curve (AUC) and other PK
parameters (Cmax, Tmax, Clearance, Volume of
Distribution)
○ Concentration on day 7
○ Concentration on day of failure (in case of
failure)
– Regarding safety
○ Type and frequency of adverse events
Protocol deviations and withdrawals
Children will be followed until day 42 whenever possible.
However, some reasons may lead to the interruption of
monitoring (such as protocol deviation, study with-
drawal, detection of a malaria infection with species
other than P. falciparum, death, severe adverse event,
loss to-follow-up…). In all cases, the date and reasons
for the interruption will be collected in the report form.
Adverse events
Safety and tolerability of AL have been previously
assessed and the treatment has been recommended for
routine clinical use. The summary of product character-
istics of study drugs will be available to clinicians to help
the assessment of all adverse events and their relation
with study drugs.
Any clinical or laboratory adverse event occurring during
the 42-day follow-up after dosing will be described by the
investigator in a specific section of the case report form.
The following information will be collected: date of onset,
nature, severity graded on a scale from 1 to 4 (minor, mod-
erate, severe, and life-threatening), seriousness, relationship
with AL, action(s) taken, date of resolution, outcome.
A physician investigator will be available on site 24h
per day for the management of adverse events. In case
of a SAE, as defined by ICH (ICH, CIOMS, European
directive 2001/CE/21), a specific SAE declaration form
will be filled in by the site principal investigator within
48 h and sent to the investigator coordinator in Epi-
centre, the Ethics Committees and the DSMB. They will
recommend any action to be taken (including early
termination of the study). In addition, ethics committees
who reviewed and approved the protocol will also
receive periodical reports of aggregated data on AEs, at
regular intervals throughout the study.
Statistical considerations
Study data will be double entered using REDCap elec-
tronic data capture tools hosted at Epicentre [33] then
data management and analysis will be performed with
STATA 12, StataCorp®, College Station, TX, according to
written data entry procedures and data management
plan.
A flowchart will present the following information:
number of patients screened, number of patients in-
fected with P. falciparum malaria, number of patients
infected by other Plasmodium species, number of pa-
tients excluded (and reasons why they were not eligible),
number of patients enrolled and analyzable in each
group of SAM and non-SAM children.
For all enrolled children, baseline characteristics will
be presented for each group (SAM versus non-SAM).
Antimalarial efficacy
Clinical and parasitological efficacy outcomes will be
presented for SAM and non-SAM children: number of
ETF, LCF, LPF, ACPR, re-infection, recrudescence,
mixed infection, by day 28 and day 42.
Two methods will be used to estimate the therapeutic
efficacy in each group:
 The Kaplan-Meier survival analysis will be used to
calculate estimates of survival without subsequent
infection in both intent-to-treat and per-protocol
populations. This analysis will allow accounting for
censored data [15, 34].
 Logistic regression analysis will be used to compare
at day 28 (and then day 42) the proportion of ACPR
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in patients for which the endpoint has been
determined, excluding those lost to follow-up or
with missing endpoint.
After univariate analyses, multivariate analyses using
survival models (time to recurrence) and logistic regres-
sion (proportion of ACPR) will be performed where the
therapeutic success will be explained by the degree of
malnutrition and other cofactors, including lumefantrine
PK profile.
Estimation of the PK profile of lumefantrine
PK modeling will estimate the lumefantrine area under
the curve, Cmax, Tmax, Volume of Distribution and
Clearance in SAM and non-SAM children using non-
linear mixed effect models (NONNEM).
The values obtained will be compared between groups,
and related to parasitological efficacy.
Estimation of parasite clearance
Regression models of the log-transformed parasite
counts will be fitted in order to estimate parasite clear-
ance using the Parasite Clearance Estimator Tool (PCE)
developed by the WorldWide Antimalarial Resistance
Network (WWARN) [30]. Parasite clearance will be
compared between groups of SAM and non-SAM chil-
dren on a regular basis during the study.
Ethical considerations
A French version of the protocol and informed consent
form has been approved by the Ethics Committee of the
Faculty of Medicine and Odonto-Stomatologie and the
Faculty of Pharmacy in Bamako, Mali and Niger Na-
tional Ethics Committee of the Ministry of Health. An
English version has been approved by MSF Ethical Re-
view Board.
Any amendment to the protocol that may affect the
rights, safety and / or welfare of the participants or the
conduct of research will be submitted again to Ethics
Committees before being implemented.
Individual data will not be disclosed to anyone outside
the research team, unless it is necessary for the proper
medical management of children (useful data can then
be shared with the physician, in respect of medical confi-
dentiality). The database will not contain any personally
identifiable information; patients are only identified by
their inclusion number.
Monitoring and good clinical practice
The study will comply with the recommendations of Good
Clinical Practice and with standards of care established by
the national health programs and the Declaration of
Helsinki. An external Good Clinical Practice monitor will
conduct regular visits to the sites, as detailed in a dedicated
monitoring plan. Data report forms will be checked on site
in relation to source documents to ensure they are
complete and clear. The monitor will also review compli-
ance with written standardized operating procedures.
For this study, a DSMB will be instituted including
members with the following expertise: pharmacometri-
cian, epidemiologist, malaria specialist, and pediatrician.
As described in a dedicated DSMB charter, it will be
responsible for regularly review the results regarding the
enrolment of patients, and the efficacy and safety of AL.
The DSMB will advise the Scientific Committee on the
continuation or, if needed the amendment or discontinu-
ation of the trial.
Risks and benefits for participants
Inclusion in the study is voluntary and will only be pos-
sible if the adult parent or guardian gives written in-
formed consent.
Participants will receive a free malaria treatment and
will benefit from active monitoring in the health facility
for 42 days. In case of treatment failure, they will receive
a rescue treatment. Concomitant diseases will also be
actively sought and promptly managed. Children with
SAM will benefit appropriate nutritional care. All the
care provided meets the highest quality standards, and is
in accordance with national guidelines.
Participants will be informed of the possible occur-
rence of side effects related to the study treatments, and
these will be systematically recorded and managed.
The constraints for the child (and caregiver) will be to
stay in the health center for the 3 days of treatment, and
then return to the study site every week for 6 weeks.
Reimbursements will be given in compensation for the
time spent for visits and travel costs, according to the
recommendations of the community leaders. During
follow-up, the child will have several capillary blood
collections that are not performed routinely, although
the total blood volume sampled will be limited to under
10 mL so is not associated with a particular risk. The
risks are fear and pain at the puncture site.
Discussion
This study will be conducted during 2013 and 2014 mal-
aria seasons in Mali, and 2014 malaria season in Niger.
Enrolments are expected to end in early 2015 and results
should be available in second semester 2015.
The study report will be discussed and circulated to
the stakeholders, including the local officials. A poster
summarizing the main results will be posted at the two
study hospitals to inform the participants. Several oral
feedback sessions will also be held on the study sites and
with scientific partners and policy makers. The results
will be published in scientific journals and reported at
international conferences.
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In the study areas, a better understanding of the efficacy
of antimalarial drugs (in SAM and non-SAM children) will
contribute to updating the protocols for case management
of malaria, and thus contribute to improving the health of
the population.
More generally, this study will provide important,
lacking information on the efficacy of AL in SAM chil-
dren and could inform further recommendations for
the management of malaria in this specific population.
It will therefore benefit all malnourished children liv-
ing in malaria-endemic areas (the entire Sahel Africa
is concerned). If our results indicate a lack of efficacy
of AL at usual doses, we will recommend evaluating
the use of increased doses through dose optimization
studies.
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